Correlation between expression of epidermal growth factor receptor and adverse reactions after chemotherapy of advanced non-small-cell lung cancer.

Zerui Hao,Jihong Zhang,Chunyan Tian,Futang Yang

doi:10.12669/pjms.315.7939

Abstract

Objective:To analyze the correlation between expression of epidermal growth factor receptor (EGFR) and adverse reactions after chemotherapy of advanced non-small-cell lung cancer (NSCLC).Methods:A total of 120 NSCLC patients who were treated in our hospital from August 2009 to September 2011 were selected as an observation group, and another 120 healthy subjects were selected as a control group. EGFR expressions in both groups were detected. The observation group was subjected to combination chemotherapy, and their shorter- and long-term prognostic outcomes, adverse reactions and mortality were recorded. Meanwhile, correlation analysis was performed.Results:The observation group had significantly higher percentage and positive rate in EGFR expression than those of the control group (P<0.05). With increasing stage and lymphatic metastasis, the positive expression rate of EGFR rose significantly (P<0.05). In the observation group, the response rate of treatment was 62.5%, and the incidence rate of adverse reactions after chemotherapy was 28.3% (34/120). The 1-, 2- and 3-year survival rates were 38.3%, 15.0% and 10.0% respectively. Multiple Logistic regression analysis showed that TNM stage, lymphatic metastasis and positive EGFR expression were the main independent risk factors for post-chemotherapy adverse reactions (P<0.05).Conclusion:Advanced NSCLC was commonly accompanied by high EGFR expression. Although chemotherapy was able to improve the prognosis and survival rate, adverse reactions were also induced, being associated with the pathological characteristics and EGFR expressions of patients.

Highlights

Lung cancer has become one of the most common malignant tumors worldwide, with the highest morbidity and mortality rates among males as well as the highest morality rate and the second highest morbidity rate among females.[1,2] In most cases, lung cancer originates from bronchial mucous epithelia or glands, for which non-small-cell lung cancer (NSCLC) accounts over 80%.3,4 NSCLC is a worldwide health problem and a leading cause of cancer-related deaths
We explored the correlation between epidermal growth factor receptor (EGFR) expression and adverse reactions after chemotherapy of advanced NSCLC
Observation Indices: Evaluation on therapeutic effects: Baseline tumor foci were subjected to regular imaging examination after treatment and the therapeutic effects were evaluated based on the changes of solid tumors as complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD)

Summary

INTRODUCTION

Lung cancer has become one of the most common malignant tumors worldwide, with the highest morbidity and mortality rates among males as well as the highest morality rate and the second highest morbidity rate among females.[1,2] In most cases, lung cancer originates from bronchial mucous epithelia or glands, for which non-small-cell lung cancer (NSCLC) accounts over 80%.3,4 NSCLC is a worldwide health problem and a leading cause of cancer-related deaths. Lung cancer has become one of the most common malignant tumors worldwide, with the highest morbidity and mortality rates among males as well as the highest morality rate and the second highest morbidity rate among females.[1,2] In most cases, lung cancer originates from bronchial mucous epithelia or glands, for which non-small-cell lung cancer (NSCLC) accounts over 80%.3,4. Platinum-containing two-agent combination regimens can increase the survival rate of NSCLC patients, adverse reactions, including hematologic and non-hematologic toxicities, are inevitable. EGF first binds EGFR to form a dimer and phosphorylates the latter, thereby initiating the intracellular signal transduction system.[12] Abnormally transduced in tumors mostly, EGFR has been paid particular attention in clinical examination and recent antitumor therapy.[13,14] it is necessary to reveal the differences between EGFR expression by observing post-chemotherapy adverse reactions. We explored the correlation between EGFR expression and adverse reactions after chemotherapy of advanced NSCLC

METHODS

RESULTS

DISCUSSION